摘要
目的探讨比索洛尔对单纯稳定期的慢性阻塞性肺疾病患者肺功能及相关炎症介质表达的影响。方法将144例慢性阻塞性肺疾病患者随机分为对照组72例和试验组72例。对照组予以口服羧甲司坦片0.5 g,每天3次;试验组在对照组的基础上,加用口服比索洛尔1.25 mg,每天1次。2组患者疗程均为12周。比较2组患者在治疗前及治疗4,8,12周时肺功能及炎症介质表达情况的差异,以及不良反应的发生率。结果治疗前后,2组患者的各项肺功能指标比较差异均无统计学意义(P>0.05)。治疗12周后,试验组患者的步行距离(341±44)m显著高于对照组(276±41)m(P<0.05)。治疗12周后,试验组C反应蛋白表达情况为(7.15±0.39),血清淀粉样A表达情况为(35.4±3.8)均低于对照组C反应蛋白表达情况(8.24±0.44)和血清淀粉样A表达情况(48.6±6.2)(P<0.05)。治疗期间,对照组未出现不良反应,试验组共发生3例不良反应,差异无统计学意义(P>0.05)。结论比索洛尔有助于降低单纯稳定期慢性阻塞性肺疾病患者炎症介质(C反应蛋白及血清淀粉样A)的表达水平,提高运动耐量,并较少影响肺功能。
Objective To investigate the effect of bisoprolol on lung function and expression of inflammation - related in patients with stable chronic obstructive pulmonary disease. Methods One hundred fourty- four chronic obstructive pulmonary disease patients were randomly divi- ded into control group and treatment group, 72 eases in each group. The control group was given phlegm tablets, 0. 5 g, three times one day. Treatment group was taken bisoprolol tablets 1.25 mg, once per day, on the basis of the treatment of control group. The expression and inflamma- tory mediators before and after treatment 4,8,12 weeks as well as the in- cidence of adverse reactions between two groups were compared. Results Before and after treatment, the indicators of lung function of both groups had no significant difference （P 〉0. 05） , while after 12 weeks of treatment, the walking distance （341 ± 44） m of treatment group was longer than that of control group （276±41 ） m（ P 〈 0.05 ）. In addition, 12 weeks of treatment, the C-reactive protein expression of （7. 15 ±0. 39） and serum amyloid A expression（35.4 ± 3.8 ）of experimental group were lower than those of control group, which were （ 8.24 ± 0. 44 ） and （48.6 ± 6. 2） （P 〈 0. 05 ）. In addition, during the treatment, no adverse reactions appeared in control group, three cases of adverse reactions exists in the experimental group, but there was no significant difference （ P 〉 O. 05 ）. Conclusion For the treatment of simple stable chronic obstructive pulmonary, bisoprolol helps to reduce the expres- sion of inflammatory mediator, improve exercise tolerance, and have less impact on pulmonary function of patients.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2015年第20期1990-1992,共3页
The Chinese Journal of Clinical Pharmacology
基金
浙江省医药卫生科技计划基金资助项目(2013ZHB008)
关键词
比索洛尔
慢性阻塞性肺疾病
C反应蛋白
炎症介质
bisoprolol
chronic obstructive pulmonary disease
C - reactive protein
inflammatory mediator
